TB-500 is a synthetic 17-amino-acid fragment of Thymosin Beta-4, containing the active actin-binding domain responsible for cell migration and tissue repair. It's a cornerstone of healing peptide protocols, especially when stacked with BPC-157.
Research-context information only. TB-500 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
Clinical Status: No human trials exist for TB-500 specifically. All protocols are extrapolated from Thymosin Beta-4 research and animal studies. This is not medical advice.
TB-500 Dosing Table
Match your vial size below — reconstitution and dose math update automatically.
500 mcg
20 units
0.2 mL
Daily SubQStandard
750 mcg
30 units
0.3 mL
Daily SubQ
2 mg
80 units
0.8 mL
2x/week SubQLoading dose (week 1-4)
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.
10 units
0.1 mL
1 mg
40 units
0.4 mL
2x/week SubQLoading
Running TB-500? Share your protocol
Anonymous · about 20 seconds · see how yours compares
Quick Reference: Standard Protocol
Dose
500 mcg (10 units on insulin syringe)
Route
Subcutaneous injection (systemic — site doesn't matter)
Timing
AM
Frequency
Every day
Cycle
8 weeks on, 8 weeks off
Vial size
10 mg
Reconstitution
2 mL bacteriostatic water → 5,000 mcg/mL
Draw amount
10 units on insulin syringe
Storage
Refrigerate, use within 28 days
Community-reported protocol: 500 mcg daily in the morning for 8 weeks, then 8 weeks off. TB-500 works systemically, so injection site location doesn't affect efficacy. For the full TB-500 profile, vendor pricing, and stacking options, see our TB-500 peptide page.
Cycling Details
The standard cycle is 8 weeks on, 8 weeks off. Tissue remodeling and healing effects build over 4-6 weeks and continue through the full 8-week window. Community protocols describe the off period as allowing receptor sensitivity to reset, with the rationale that cycling may prevent receptor downregulation — though no direct TB-500 human trial data exists to confirm this.
Unlike some peptides, TB-500 protocols use consistent daily dosing throughout the cycle — no loading or tapering needed. The daily protocol is preferred because TB-500's half-life supports once-daily dosing, and consistent levels optimize the cellular repair processes it targets (Kim & Bhatt, 2013).
Enhanced Protocol (Community)
Note: The standard protocol above reflects the common community protocol. The enhanced protocol below is based on community experience.
2–2.5 mg twice weekly
2x per week
Weekly total
4–5 mg (vs 3.5 mg standard)
Use case
Less frequent injections, mimics TB-4 research protocols
Some users prefer twice-weekly pulsing for convenience. Weekly totals are similar, but daily dosing provides more stable tissue levels.
Routes of Administration
Subcutaneous (standard): Protocols describe injecting anywhere convenient — abdomen, thigh, upper arm. TB-500 distributes systemically regardless of site. A 29-31 gauge insulin syringe is commonly used.
Intramuscular: Occasionally used but offers no advantage over subcutaneous for a systemic peptide like TB-500.
Not recommended: Oral (peptide degradation), nasal (no data), topical (molecular weight too large).
Reconstitution Quick Reference
2 mL
5,000 mcg/mL
10 mg vial + 2 mL BAC water = 5,000 mcg/mL. A 500 mcg dose draws to 10 units on an insulin syringe under this reconstitution. One vial covers 20 days at this protocol.
Community protocols describe gentle swirling — not shaking — then refrigerating at 2-8°C and using within 28 days. For the full step-by-step walkthrough, see the TB-500 Reconstitution Guide.